Acquisition FAQs for Celgene Shareholders

Who do I contact to get information about receiving the merger consideration?

What happened with my existing Celgene shares?

What are the tax consequences to me of receiving the merger consideration (i.e., 1 share of Bristol Myers Squibb stock, $50 cash and 1 CVR for each of my vested Celgene shares)?

Is the exchange of my Celgene common shares for shares of Bristol Myers Squibb common stock and cash mandatory?

How do I exchange my Celgene shares?

What if I can’t locate all of my Celgene share certificates?

What if I have certificated Celgene shares in more than one account?

ABRAXIS/ABRAXANE Contingent Value Right (CVR)

What happened to my existing Abraxis/Abraxane CVR?

Please remind me what triggers a payout under the Abraxis /Abraxane CVR (CELG RT, formerly CELGZ)?

Who is the exchange agent?

Bristol Myers Squibb CVR (“BMS CVR”)

Bristol Myers Squibb Statement on Status of Liso-cel Application  and Contingent Value Rights as of January 1, 2021

Bringing liso-cel to patients with 3L+ Large B Cell Lymphoma is a top priority for Bristol Myers Squibb. With the lapsing of the PDUFA date, the application remains under review by the United States Food and Drug Administration (FDA). Since the last update on November 16, 2020, the following has occurred:

  • The inspection of the viral vector 3rd party manufacturing plant took place from December 3, 2020 to December 10, 2020
  • Lonza and BMS expeditiously responded to observations received at the close of the inspection within 8 days
  • BMS received Information Requests which were also rapidly responded to and there are currently no outstanding Information Requests at this time.

We will continue to work closely with the FDA to bring this therapy to patients as quickly as possible.

For CVR holders: Because the milestone of approval of liso-cel by December 31, 2020 was not met, the CVR agreement has automatically terminated in accordance with its terms, the security will no longer trade on the NYSE, and the CVRs are no longer eligible for payment.

What happened to my BMS CVR? 

What consideration was I eligible to receive under a BMS CVR?

Can I sell my CVR?

What is the ticker for the CVR?


FAQs for BMY Shareholders

Frequently asked questions about Bristol Myers Squibb shares.

Learn More